News

Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide.

Oncology nurse experts review their experiences with newcomers for the treatment of advanced endometrial cancer and exchange best practices in caring for this population.

Patients with non-small cell lung cancer harboring exon 20 insertion mutations whose disease progressed after platinum-based chemotherapy continued to show responses to amivantamab in a long-term analysis of the CHRYSALIS trial.

To evaluate the prevalence of financial toxicity and observe the effect of Coverage and Cost-of-Care Links, a program providing financial navigation, investigators initiated a nonrandomized study.

Narrative medicine is relevant to health care professions and can be used to enhance patient as well as the clinician’s experiences.

The FDA has granted full approval to pembrolizumab (Keytruda) for certain adult and pediatric patients with advanced MSI-H or dMMR solid tumors.

In the all-comer population, the overall response rate was 33.8%, including a complete response rate of 7.5% and a partial response rate of 26.3%.

Hematologists have developed a framework of the core symptoms caregivers should look out for when caring for a patient who has just received CAR T-cell therapy.

Major findings demonstrated that patients with colorectal cancer experienced generally low symptom severity with most symptoms remaining stable or improving following treatment.

La-Urshular Brock, MSN, FNP-BC, CNM, discusses how a better understanding of HER2-low status may necessitate more testing for certain patients with breast cancer.

Research presented at the 2023 Society of Gynecologic Oncology Annual Meeting On Women’s Health suggests that the Carolina frailty index score may be useful for women with ovarian cancer.

The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed a demonstrable correlation in total scores, according to an analysis of women with advanced endometrial cancer.

The primary overall survival analysis of the phase 3 ZUMA-7 trial favors axicabtagene ciloleucel over standard of care therapy.

A cohort study identified factors associated with late deaths in childhood cancer survivors.

Inpatient infusion was linked with greater comorbidity burden and increased likelihood of adverse effects in patients with follicular lymphoma who received CAR T-cell therapy, but not in those with mantle cell lymphoma.

Patients with metastatic squamous non–small cell lung cancer experienced a clinically meaningful survival benefit when treated with pembrolizumab in combination with chemotherapy.

The state-of-the-art facility represents the organization’s vision of global cancer care

In the United States, only 27 institutions have been awarded the Gold level “Center of Excellence” by the International Cardio-Oncology Society (IC-OS). The Cardio-Oncology Program at the Georgia Cancer Center is proud to be one of those 27 institutions.

A television commercial produced by Florida Cancer Specialists & Research Institute, LLC (FCS) has been recognized with a Silver ADDY® by the American Advertising Awards, which honors excellence in advertising as judged by creative industry professionals around the world.

The gift is from the estate of Tom and Catherine Culley, longtime residents of the East Coast and worldwide travelers.

Agnes Pilecki, BSN, RN, a nurse on Barbara Ann Karmanos Cancer Institute’s bone marrow transplant unit, has been named the Metro Detroit Oncology Nursing Society’s (MDONS) Outstanding Oncology Nurse of the Year.

The Barbara Ann Karmanos Cancer Institute is now seeing patients at the new Karmanos Cancer Institute – Roseville.

Narrative oncology is the practice of funneling our experience in health care into stories that are emotional and humanistic.

The implementation of a nonpharmacologic pain intervention bundle helped decrease opioid use among patients recovering from gynecologic and urologic surgeries at a comprehensive cancer center.

Retifanlimab has received accelerated approved for patients with metastatic or recurrent, locally advanced merkel cell carcinoma.

Among 5 patients who achieved a response with JTX-8064/pimivalimab, tumor reduction remained consistent for more than 6 months on study treatment.

The International Pediatric Fever and Neutropenia Guideline Panel have reconvened and released a 2023 clinical practice guideline update.

Patritumab deruxtecan generated activity in patients with metastatic or unresectable EGFR-mutated non–small cell lung cancer and HER3-expressing breast cancer.

A retrospective cohort demonstrated that patients who are treated with antibiotics within 1 year before immune checkpoint inhibitor therapy may experience worse overall survival.

Patients with multiple myeloma who received subcutaneous daratumumab experienced reduced clinic times compared with those who received the agent intravenously.